Search results
Showing 1006 to 1020 of 1106 results for infections
This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years. Care of babies and children born preterm or with low birth weight is not covered. The guideline does not give detailed advice on what constitutes a healthy diet.
Focal therapy using cryoablation for localised prostate cancer (HTG284)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for HTG284Show all sections
Sections for HTG284
hospital stays, revision rates, neurological complications and surgical site infections compared with the posterior and anterolateral...
Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)
This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.
Respiratory tract infections (self-limiting): prescribing antibiotics (CG69)
We have withdrawn this guideline and incorporated the relevant recommendations from it into NICE's antimicrobial prescribing guidelines on sinusitis, sore throat, otitis media and cough.
UroShield for preventing catheter-associated urinary tract infections (MTG69)
We have moved Medical technologies guidance 69 to become HealthTech guidance 620. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
UroShield for preventing catheter-associated urinary tract infections (MIB191)
This advice has been updated and replaced by NICE healthtech guidance 620.
Sexually transmitted infections and under-18 conceptions: prevention (PH3)
This guidance has been updated and replaced by NICE guideline NG221.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Read biographies for all members of NICE's indicator advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
Leukomed Sorbact for preventing surgical site infection (MTG55)
We have moved Medical technologies guidance 55 to become HealthTech guidance 567. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.